Cardinal Health (CAH) is trading down at $231.55 (-0.81%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.
Cardinal Health revenue & net income history (FY2017–FY2026)
| FY2017Jun 2017 | FY2018Jun 2018 | FY2019Jun 2019 | FY2020Jun 2020 | FY2021Jun 2021 | FY2022Jun 2022 | FY2023Jun 2023 | FY2024Jun 2024 | FY2025Jun 2025 | FY2026Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $130.0B | $136.8B | $145.5B | $152.9B | $162.5B | $181.3B | $205.0B | $226.8B | $222.6B | $254.2B |
| Growth (year over year) | +6.9% | +5.3% | +6.4% | +5.1% | +6.2% | +11.6% | +13.0% | +10.7% | −1.9% | +14.2% |
| Gross profit | $6.54B | $7.18B | $6.83B | $6.87B | $6.78B | $6.48B | $6.87B | $7.41B | $8.17B | $9.77B |
| Gross margin | 5.0% | 5.2% | 4.7% | 4.5% | 4.2% | 3.6% | 3.4% | 3.3% | 3.7% | 3.8% |
| Operating income | $2.12B | $126.0M | $2.06B | −$4.10B | $472.0M | −$607.0M | $752.0M | $1.24B | $2.27B | $2.61B |
| Operating margin | 1.6% | 0.1% | 1.4% | −2.7% | 0.3% | −0.3% | 0.4% | 0.5% | 1.0% | 1.0% |
| Net income | $1.29B | $256.0M | $1.36B | −$3.70B | $611.0M | −$938.0M | $330.0M | $852.0M | $1.56B | $1.71B |
| Net margin | 1.0% | 0.2% | 0.9% | −2.4% | 0.4% | −0.5% | 0.2% | 0.4% | 0.7% | 0.7% |
| EPS (diluted) | $4.03 | $0.81 | $4.53 | −$12.61 | $2.08 | −$3.37 | $1.26 | $3.45 | $6.45 | $7.23 |
| Balance sheet | ||||||||||
| Cash and equivalents | $6.88B | $1.76B | $2.53B | $2.77B | $3.41B | $4.72B | $4.08B | $5.13B | $3.87B | $4.86B |
| Total assets | $40.1B | $40.0B | $41.0B | $40.8B | $44.5B | $43.9B | $43.3B | $45.1B | $53.1B | $57.3B |
| Total liabilities | $33.3B | $33.9B | $34.6B | $39.0B | $42.8B | $44.8B | $46.3B | $48.3B | $55.8B | $60.0B |
| Long-term debt | $9.07B | $8.01B | $7.58B | $6.76B | $5.37B | $4.74B | $3.91B | $4.66B | $7.98B | $7.00B |
| Shareholders' equity | $6.81B | $6.06B | $6.33B | $1.79B | $1.79B | −$709.0M | −$2.96B | −$3.21B | −$2.78B | −$2.88B |
| Cash flow | ||||||||||
| Operating cash flow | $1.18B | $2.77B | $2.72B | $1.96B | $2.43B | $3.17B | $2.84B | $3.76B | $2.40B | $5.17B |
| Capital expenditure | $387.0M | $384.0M | $328.0M | $375.0M | $400.0M | $387.0M | $481.0M | $511.0M | $547.0M | $649.0M |
| Free cash flow | $797.0M | $2.38B | $2.39B | $1.58B | $2.03B | $2.79B | $2.36B | $3.25B | $1.85B | $4.53B |
| Dividends paid | $577.0M | $581.0M | $577.0M | $569.0M | $573.0M | $559.0M | $525.0M | $499.0M | $494.0M | $491.0M |
| Share buybacks | $600.0M | $550.0M | $600.0M | $350.0M | $200.0M | $1.00B | $2.00B | $750.0M | $765.0M | $1.36B |
| Q4 FY24†Jun 2024 | Q1 FY25Sep 2024 | Q2 FY25Dec 2024 | Q3 FY25Mar 2025 | Q4 FY25†Jun 2025 | Q1 FY26Sep 2025 | Q2 FY26Dec 2025 | Q4 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $59.9B | $52.3B | $55.3B | $54.9B | $60.2B | $64.0B | $65.6B | — |
| Growth (year over year) | +12.1% | −4.3% | −3.8% | +0.0% | +0.5% | +22.4% | +18.8% | — |
| Gross profit | $1.88B | $1.90B | $1.94B | $2.12B | $2.20B | $2.32B | $2.40B | — |
| Gross margin | 3.1% | 3.6% | 3.5% | 3.9% | 3.7% | 3.6% | 3.7% | — |
| Operating income | $401.0M | $568.0M | $549.0M | $730.0M | $428.0M | $668.0M | $707.0M | — |
| Operating margin | 0.7% | 1.1% | 1.0% | 1.3% | 0.7% | 1.0% | 1.1% | — |
| Net income | $235.0M | $416.0M | $400.0M | $506.0M | $239.0M | $450.0M | $467.0M | — |
| Net margin | 0.4% | 0.8% | 0.7% | 0.9% | 0.4% | 0.7% | 0.7% | — |
| EPS (diluted) | $0.93 | $1.70 | — | — | — | $1.88 | — | — |
| Balance sheet | ||||||||
| Cash and equivalents | $5.13B | $2.87B | $3.81B | $3.33B | $3.87B | $4.59B | $2.78B | $4.86B |
| Total assets | $45.1B | $43.1B | $47.0B | $49.9B | $53.1B | $55.2B | $58.1B | $57.3B |
| Total liabilities | $48.3B | $46.3B | $49.9B | $51.8B | $55.8B | $58.0B | $60.8B | $60.0B |
| Long-term debt | $4.66B | $4.22B | $7.06B | $7.14B | $7.98B | $8.98B | $8.35B | $7.00B |
| Shareholders' equity | −$3.21B | −$3.28B | −$2.99B | −$2.95B | −$2.78B | −$2.88B | −$2.88B | −$2.88B |
| Cash flow | ||||||||
| Operating cash flow | $2.08B | −$1.65B | −$396.0M | $2.91B | $1.53B | $973.0M | $686.0M | — |
| Capital expenditure | $193.0M | $90.0M | $99.0M | $126.0M | $232.0M | $108.0M | $131.0M | — |
| Free cash flow | $1.89B | −$1.74B | −$495.0M | $2.79B | $1.29B | $865.0M | $555.0M | — |
| Dividends paid | $122.0M | $128.0M | $122.0M | $124.0M | $120.0M | $129.0M | $122.0M | — |
| Share buybacks | $0 | $375.0M | $15.0M | $375.0M | $0 | $375.0M | $383.0M | — |
From Cardinal Health's 10-K and 10-Q filings with the SEC; its fiscal year ends in June. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Cardinal Health
Cardinal Health Technologies, LLC doing business as Cardinal Health, is an American multinational health care services company, and the 15th highest revenue generating company in the United States. Headquartered in Dublin, Ohio, the company specializes in the distribution of pharmaceuticals and medical products, serving more than 100,000 locations. The company also manufactures medical and surgical product, including gloves, surgical apparel, and fluid management products. In addition, it operates one of the largest networks of radiopharmacies in the U.S. Cardinal Health provides medical products to over 75 percent of hospitals in the United States.
Source: Wikipedia — Cardinal Health
- Headquarters
- Dublin, Ohio From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- BDX Becton Dickinson
- BIIB Biogen
- BMY Bristol Myers Squibb
- BSX Boston Scientific
- CI Cigna
- CNC Centene Corporation
- COO Cooper Companies (The)
- COR Cencora